Up 22% in a month, can the Imugene share price extend its rally?

A woman stretches her arms into the sky as she rises above the crowd.A woman stretches her arms into the sky as she rises above the crowd.

The Imugene Limited (ASX: IMU) share price has lifted into the green in afternoon trade on Wednesday.

At the time of writing, the share is swapping hands 3.26% higher at 23.75 cents apiece. For context, the All Ordinaries Index (ASX: XAO) is down 0.35%.

Imugene bounced from a 52-week low of 14 cents on 14 June and now trades around 70% higher off that mark, or around 22% in the past month.

What’s up with the Imugene share price?

It had been all downhill for Imugene shareholders in the eight months leading to June. Shares had reverted from a peak of 60.5 cents on 9 November and sailed down to yearly lows by then.

However, healthcare shares have caught a bid in the new financial year, with the S&P/ASX Health Care Index (ASX: XHJ) up around 10% on the month.

The moves appear to have inflected positively on the Imugene share price, with both instruments moving in relatively close succession of each other this year to date, as seen below.

TradingView Chart

Meanwhile, the share is rated a buy from 100% of the brokers covering the company, according to Refinitiv Eikon data.

The consensus price target from this list is 56 cents per share, implying a considerable amount of upside potential should the brokers be correct.

Further, Immugene released its quarterly results last month, reinstating positive results from its final HER-Vaxx HERIZON Phase 2 trial.

It also noted a cash balance of approximately $100 million dollars leaving the quarter. Meanwhile, the company spent $8.1 million on research and development for the quarter.

In the last 12 months, the Imugene share price has slipped more than 20% into the red, and is down 40% this year to date.

The post Up 22% in a month, can the Imugene share price extend its rally? appeared first on The Motley Fool Australia.

Should you invest $1,000 in Imugene Limited right now?

Before you consider Imugene Limited, you’ll want to hear this.

Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and Imugene Limited wasn’t one of them.

The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.

See The 5 Stocks
*Returns as of July 7 2022

(function() {
function setButtonColorDefaults(param, property, defaultValue) {
if( !param || !param.includes(‘#’)) {
var button = document.getElementsByClassName(“pitch-snippet”)[0].getElementsByClassName(“pitch-button”)[0];
button.style[property] = defaultValue;
}
}

setButtonColorDefaults(“#43B02A”, ‘background’, ‘#5FA85D’);
setButtonColorDefaults(“#43B02A”, ‘border-color’, ‘#43A24A’);
setButtonColorDefaults(“#fff”, ‘color’, ‘#fff’);
})()

More reading

Motley Fool contributor Zach Bristow has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

from The Motley Fool Australia https://ift.tt/r1gbL6V

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s